Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, dose escalation, phase I/II trial evaluating the safety, tolerability, pharmacokinetic, pharmacodynamic and efficacy of ALLO 715 patients with R/R multiple myeloma, who have progressed on at least two lines of prior therapy

Trial Profile

Open-label, dose escalation, phase I/II trial evaluating the safety, tolerability, pharmacokinetic, pharmacodynamic and efficacy of ALLO 715 patients with R/R multiple myeloma, who have progressed on at least two lines of prior therapy

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Allo 715 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Allogene Therapeutics
  • Most Recent Events

    • 03 Dec 2018 According to an Allogene Therapeutics media release, the company plans to submit an Investigational New Drug (IND) application for ALLO-715 and initiate a Phase 1 clinical trial in 2019.
    • 15 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top